ArticleInternational journal of general medicine2026
Whole Exome Sequencing Reveals Potential Single Nucleotide Polymorphisms and Copy Number Variations in 26 Sporadic Patients with Immature Teratoma.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immature teratoma is a malignant tumor and accounts for 1%-3% of ovary teratoma. The objective of this study was to find the potential single nucleotide polymorphisms (SNPs), copy number variations (CNVs) and drug targets in the immature teratoma. Material and Methods: Genomic DNA was extracted from peripheral blood of 26 sporadic immature teratoma patients for whole exome sequencing (WES) analysis to detect germline variants. SNPs and CNVs were identified, followed by the analysis of physical/chemical properties and conserved domain of mutated genes. Functional enrichment and protein-protein interaction (PPI) analysis of mutated genes was performed, followed by pharmacogenomic analysis. Finally, SNPs, CNVs and mRNA expression of mutated genes were investigated in ovarian cancer by using the online databases. Results: A total of 24 common mutated genes were identified in 26 patients. Among which, 5 common mutated genes with common mutation sites were identified, including 2 frameshift mutant genes (MYPOP and FRG2C) and 3 nonsynonymous mutant genes (CNTNAP3, GPRIN2 and MUC3A). After mutation, molecular weight of MYPOP, FRG2C, CNTNAP3, GPRIN2 and MUC3A changed slightly. In the PPI network, MUC12 (with the highest degree) interacted with GALNT12, MUC3A and FCGBP. Based on the pharmacogenomic analysis, MUC2 was predicted to be a potential drug target of CHEMBL35482, FLUOROURACIL and DECITABINE. According to the functional analysis, MUC3A, MUC2 and MUC12 were involved in biological processes of activation of the innate immune response. The mutation frequency of FCGBP and CNTNAP3 was rare and had a higher amplification frequency in ovarian cancer. In addition, 2 common CNVs (deletion state) were screened out, which involving 6 genes, such as RP11. Conclusion: This study identified some potential SNPs and CNVs, which may contribute to clarifying the pathogenesis of immature teratoma and provide potential biomarkers and drug targets for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.